The role of non-classical MHC class I molecules in immune responses to Mycobacterium tuberculosis infection
非经典 MHC I 类分子在结核分枝杆菌感染免疫反应中的作用
基本信息
- 批准号:10402266
- 负责人:
- 金额:$ 56.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-14 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:Activities of Daily LivingAdoptive TransferAnimal ModelAntigen PresentationAntigensAttenuatedAutoimmune DiseasesBacterial ModelBiological AssayBiological Response ModifiersCD8-Positive T-LymphocytesCD8B1 geneCharacteristicsDevelopmentElementsEquilibriumExhibitsFlow CytometryFrequenciesFutureGene Expression ProfileGenerationsGeneticGlycopeptidesHLA G antigenHistocompatibility Antigens Class IHomologous GeneHost DefenseHumanImmune responseImmunityImmunodominant AntigensImmunologic MemoryIn VitroIndividualInterruptionKLRD1 geneKineticsKnowledgeLeadMHC antigenMediatingMemoryModelingMouse StrainsMucous MembraneMusMutant Strains MiceMycobacterium InfectionsMycobacterium tuberculosisMycobacterium tuberculosis H37RvMycobacterium tuberculosis antigensPeptidesPhenotypePlayPopulationPredispositionPreventive vaccinePropertyProteinsPulmonary PathologyQa-1 AntigenReceptor ActivationRegulatory T-LymphocyteRoleSurfaceT cell regulationT cell responseT memory cellT-Cell ActivationT-LymphocyteT-Lymphocyte SubsetsT-cell receptor repertoireThymus GlandTuberculosisVaccinationVaccinesVirulentVirus DiseasesVitamin B Complexbasecytotoxic CD8 T cellsmicroorganism antigenmouse modelmycobacterialnovelpeptide vaccinationpreventprotective efficacyreceptorresponsetranscriptome sequencingtuberculosis immunityvaccination against tuberculosisvaccination strategyvaccine candidatevaccine developmentvaccine strategy
项目摘要
PROJECT SUMMARY
While current Mycobacterium tuberculosis (Mtb) vaccine development has primarily focused on CD4+ and MHC
Ia-restricted CD8+ T cell responses, increasing evidence shows that non-conventional CD8+ T cells restricted by
MHC Ib molecules can recognize diverse microbial antigens and contribute to protection against Mtb infection.
For example, H2-M3, Qa-1/HLA-E, Qa-2/HLA-G, MR1, and CD1 have been implicated in the host immune
response against Mtb in mice and/or humans. However, most of these studies have only examined the function
of MHC Ib-restricted T cells during the primary response to Mtb infection. Given that several subsets of MHC Ib-
restricted T cells exhibit "innate-like" T cell characteristics and undergo unique thymic selection, it is unclear
whether and which MHC Ib-restricted CD8+ T cell population can mount a memory response during Mtb infection.
Furthermore, some MHC Ib molecules also act as regulators of the immune responses aside from their role in
antigen presentation. In particular, Qa-1 can regulate immune responses against Mtb through the interaction
with inhibitory CD94/NKG2A receptors and regulatory CD8+ T cells. To better understand the diverse role of
MHC Ib molecules play in immune responses against Mtb, this proposal seeks to determine whether the
composition and function of MHC Ib-restricted CD8+ T cell subsets in the secondary response differs from the
primary response, as well as how individual Qa-1-mediated regulatory mechanisms contribute to the immune
response against Mtb. In Aim 1, we propose to compare the kinetics, function, and protective ability of MHC Ib-
restricted CD8+ T cell responses during primary and secondary Mtb infection in mice, and evaluate the protective
efficacy of vaccination with Qa-1/HLA-E-restricted Mtb peptides. We will use a novel vaccination and re-
challenge model that allows for complete clearance of an attenuated Mtb strain prior to challenge with fully
virulent Mtb to study memory responses. These studies will allow us to identify the dominant MHC Ib-restricted
CD8+ T cells and the Mtb antigens they present during the secondary immune response, their ability to mediate
protective immunity against Mtb, and peptide vaccination strategies to increase the frequency of these effector
CD8+ T cells. In Aim 2, we propose to investigate the mechanisms by which Qa-1 regulates immune responses
during Mtb infection, with a focus on how inhibitory CD94/NKG2A receptors and suppressive Qa-1-restricted
CD8+ Tregs individually contribute to the regulation of T cell responses during Mtb infection. To study these
mechanisms, we will use mouse strains with genetic interruption of Qa-1’s interaction with individual receptors.
These studies will allow us to identify how Qa-1 is able contribute to the balance between effector and regulatory
immune responses for better protective immunity against Mtb. The combined results from our studies will yield
a better understanding of how MHC Ib molecules and MHC Ib-restricted T cells contribute to the overall immune
response against Mtb, for the development of better future vaccine strategies.
项目摘要
虽然目前结核分枝杆菌(Mtb)疫苗的开发主要集中在CD 4+和MHC
Ia限制性CD 8 + T细胞应答,越来越多的证据表明,受Ia限制的非常规CD 8 + T细胞
MHC Ib分子可以识别多种微生物抗原,并有助于保护免受Mtb感染。
例如,H2-M3、Qa-1/HLA-E、Qa-2/HLA-G、MR 1和CD 1已经涉及宿主免疫应答。
在小鼠和/或人中抗Mtb的应答。然而,这些研究中的大多数仅检查了
在对Mtb感染的初级应答期间,MHC-Ib-限制性T细胞。考虑到MHC Ib的几个子集-
限制性T细胞表现出“先天性”T细胞特征,并经历独特的胸腺选择,目前尚不清楚
在Mtb感染期间,MHCIb限制性CD 8 + T细胞群是否以及哪种可以产生记忆应答。
此外,一些MHC Ib分子除了在免疫反应中发挥作用外,还充当免疫反应的调节剂。
抗原呈递特别地,Qa-1可以通过与Mtb的相互作用来调节针对Mtb的免疫应答。
抑制性CD 94/NKG 2A受体和调节性CD 8 + T细胞。为了更好地理解不同的角色,
MHC Ib分子在抗结核分枝杆菌的免疫反应中起作用,这项提议试图确定MHC Ib分子是否在抗结核分枝杆菌的免疫反应中起作用。
MHC Ib限制性CD 8 + T细胞亚群在继发性应答中的组成和功能不同于
主要反应,以及如何个人Qa-1介导的调节机制有助于免疫
对结核分枝杆菌的反应在目的1中,我们提出比较MHC Ib-1的动力学、功能和保护能力。
在小鼠中,在原发性和继发性Mtb感染期间,限制性CD 8 + T细胞应答,并评估保护性Mtb抗体的作用。
用Qa-1/HLA-E限制性Mtb肽接种的效力。我们将使用一种新的疫苗,
攻击模型,其允许在用完全抗结核抗体攻击之前完全清除减毒的Mtb菌株。
致命的结核分枝杆菌来研究记忆反应这些研究将使我们能够确定占主导地位的MHC Ib限制性
CD 8 + T细胞和它们在二次免疫应答期间呈递的Mtb抗原,它们介导免疫应答的能力,
针对Mtb的保护性免疫,以及增加这些效应子的频率的肽疫苗接种策略。
CD 8 + T细胞。在目的2中,我们提出研究Qa-1调节免疫应答的机制
在Mtb感染期间,重点关注抑制性CD 94/NKG 2A受体和抑制性Qa-1限制性
CD 8 + T淋巴细胞在结核分枝杆菌感染过程中单独参与调节T细胞应答。研究这些
为了进一步研究Qa-1的作用机制,我们将使用具有Qa-1与单个受体相互作用的遗传中断的小鼠品系。
这些研究将使我们能够确定Qa-1如何能够促进效应和调节之间的平衡。
免疫应答以获得针对Mtb的更好的保护性免疫。综合我们的研究结果
更好地理解MHC Ib分子和MHC Ib限制性T细胞如何促进整体免疫
对结核分枝杆菌的反应,为更好的未来疫苗战略的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chyung-Ru Wang其他文献
Chyung-Ru Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chyung-Ru Wang', 18)}}的其他基金
A new mouse model to study the function of CD1b-restricted germline encoded, mycolyl lipid-reactive (GEM) T cells
一种新的小鼠模型,用于研究 CD1b 限制的种系编码的菌基脂质反应性 (GEM) T 细胞的功能
- 批准号:
10727275 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
The regulation and functions of Group 1 CD1-restricted T cells
第 1 组 CD1 限制性 T 细胞的调节和功能
- 批准号:
10779737 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
The role of non-classical MHC class I molecules in immune responses to Mycobacterium tuberculosis infection
非经典 MHC I 类分子在结核分枝杆菌感染免疫反应中的作用
- 批准号:
9918253 - 财政年份:2018
- 资助金额:
$ 56.74万 - 项目类别:
Development of Lipid-based Nanoparticle Vaccines Against Mycobacterium tuberculosis
抗结核分枝杆菌脂质纳米颗粒疫苗的研制
- 批准号:
9298853 - 财政年份:2017
- 资助金额:
$ 56.74万 - 项目类别:
The Role of Group 1 CD1-Restricted T Cells in Atherosclerosis
第 1 组 CD1 限制性 T 细胞在动脉粥样硬化中的作用
- 批准号:
8603279 - 财政年份:2013
- 资助金额:
$ 56.74万 - 项目类别:
The Role of Group 1 CD1-Restricted T Cells in Atherosclerosis
第 1 组 CD1 限制性 T 细胞在动脉粥样硬化中的作用
- 批准号:
8451723 - 财政年份:2013
- 资助金额:
$ 56.74万 - 项目类别:
Group 1 CD1 in Infectious Disease and T Cell Development
第 1 组 CD1 在传染病和 T 细胞发育中的作用
- 批准号:
6828264 - 财政年份:2003
- 资助金额:
$ 56.74万 - 项目类别:
Group 1 CD1 in Infectious Disease and T Cell Development
第 1 组 CD1 在传染病和 T 细胞发育中的作用
- 批准号:
7152581 - 财政年份:2003
- 资助金额:
$ 56.74万 - 项目类别:
Group 1 CD1 in Infectious Disease and T Cell Development
第 1 组 CD1 在传染病和 T 细胞发育中的作用
- 批准号:
7994164 - 财政年份:2003
- 资助金额:
$ 56.74万 - 项目类别:
Group 1 CD1 in Infectious Disease and T Cell Development
第 1 组 CD1 在传染病和 T 细胞发育中的作用
- 批准号:
7650923 - 财政年份:2003
- 资助金额:
$ 56.74万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 56.74万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 56.74万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 56.74万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 56.74万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 56.74万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 56.74万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 56.74万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 56.74万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 56.74万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 56.74万 - 项目类别: